ABSTRACT
INTRODUCTION
Transplant renal artery stenosis (TRAS) is a recognised and potentially treatable cause in post-transplant hypertension, allograft dysfunction, and even graft loss. Its incidence varies widely from 1% to 23%, depending on the definition and diagnostic techniques used.
1 Endovascular intervention, namely, percutaneous transluminal angioplasty (PTA) with or without stent placement is commonly the initial treatment of choice to restore kidney perfusion, apart from surgical intervention and conservative treatment. In the current study, we retrospectively evaluated the technical procedures, technical success rate, clinical success rate, and intermediate-and long-term clinical outcomes in patients with TRAS after percutaneous endovascular intervention in the Chinese population.
METHODS

Patient Group
From September 2003 to January 2012, 44 consecutive procedures including 17 PTA and 27 stenting in 35 patients were performed for TRAS in the Prince of Wales Hospital and North District Hospital in Hong Kong. The clinical diagnosis of TRAS was based on uncontrolled refractory or new-onset hypertension, or allograft dysfunction, and / or Doppler ultrasound suspicion.
Definitions of hypertension and renal insufficiency provided by Rundback et al 2 and Beecroft et al 3 were adopted as below:
• Hypertension was considered if (i) blood pressure increased from baseline, (ii) there was accelerated hypertension (sudden worsening of previously controlled hypertension), or (iii) there was refractory hypertension (hypertension resistant to treatment with at least three medications of different classes).
• Elevated creatinine levels necessitating renal salvage defined as (i) sudden unexplained worsening of renal function (increased serum creatinine level of >10% over baseline), and / or (ii) impairment of renal function secondary to antihypertensive treatment.
• Doppler ultrasound criteria for significant TRAS included peak systolic velocity of >200 cm/s, with or without damped flow in the intrarenal arteries.
TRAS with haemodynamic significance was defined as angiographic luminal diameter stenosis of ≥50%, 2 or translesional pressure gradient of >15%.
1 Two patients with early graft failure due to acute graft rejection were excluded from our study. No single case was declined during the study period. 
Operators
A total of three chief operators were involved in our study. The majority of cases (>90%) were performed by an operator who had more than 10 years of experience in interventional radiology. The remaining two operators had around 5 years of experience at the time of performing the procedure.
Procedures
In each intervention, diagnostic transplant renal arteriography was initially performed via a femoral arterial approach in the majority of patients. Transbrachial approach was adopted in one patient due to infeasibility of femoral approach ( Figure 1 ). An ipsilateral or contralateral femoral approach was chosen based on the type and angle of surgical anastomosis.
Non-selective ipsilateral iliac arteriography was performed to exclude any inflow or pre-anastomotic lesion and determine number of renal arteries, before the transplant renal artery was cannulated selectively, in postero-anterior or any other projection to best profile the stenosis. After proper calibration, percentage of stenosis was determined by the ratio of the diameter of the stenosed segment with that of a relatively normal segment of renal artery.
Nonionic iodinated contrast medium was utilised. The volume of contrast agent was kept to minimum to reduce the risk of nephrotoxicity. In the majority of cases, heparin sodium was administered intra-arterially (1000-3000 IU).
The stenoses were negotiated using a guidewire (either a 0.014 / 0.018 inch micro-guidewire or 0.035 Terumo guidewire), over which balloon angioplasty or selfexpandable stent placement (range, 2.5-8 mm in diameter) or both were performed. Post-PTA or stenting arteriogram was obtained to evaluate technical success. Primary stenting was the preferred treatment of choice in angiographically confirmed TRAS, in consensus with the referring clinician. In some cases where anatomical problem of the anastomosis was a concern, balloon angioplasty was performed instead. In few cases of marginal TRAS, angioplasty was the only treatment offered. Among all the 27 stenting procedures, the majority (n = 21) were primary stenting, five were a combination of PTA and stent placement, and one involved stent insertion after unsuccessful PTA.
All patients were treated with antiplatelet drugs (acetyl salicylic acid 80 mg to 160 mg) for an infinite period after the procedure.
Outcome Evaluation
Technical success, complications, clinical parameters including dialysis-free graft survival, serum creatinine level, systolic arterial blood pressure (SBP) and diastolic arterial blood pressure (DBP), and number of antihypertensive medications before and after intervention were assessed and compared. Technical success after percutaneous intervention was defined as residual stenosis of <30%, no flow-limiting dissection, and a residual peak SBP gradient of <10% of the SBP across the lesion. 2, 3 Complications were considered as procedure-related if documented within 30 days of the percutaneous intervention, and classified as major or minor based on criteria established by the Standards of Practice Committee of the Society of Interventional Radiology.
4
Patient follow-ups were made in routine clinic visits, with blood pressure monitoring and blood investigations for serum creatinine obtained at 3 months, 1 year, and 2 years (blood pressure only). The mean of three consecutive serum creatinine levels before the intervention was obtained as baseline serum creatinine. 
Statistical Analysis
Two-tailed Student's t-test was employed to analyse the differences between the mean SBP and DBP, and mean serum creatinine level before and after intervention. The number of antihypertensive medications was compared with the use of Wilcoxon signed rank test. Graft survival was estimated using Kaplan-Meier method. Categorical variables were compared with contingency tables by means of chi-square test or Fisher's exact test. Statistical Package for the Social Sciences (SPSS) version 20 was used for analysis. The statistical significance level was defined as p < 0.05.
RESULTS
Baseline Patient Characteristics
The baseline demographic data are summarised in Table 1 . The majority of the cohort had cadaveric renal transplantation (97.1%), with end-to-side arterial anastomosis to the external iliac artery (80.0%). Peri-anastomosis was the most common site of arterial stenosis (85.7%). The interval between renal transplantation and initial diagnosis of TRAS varied, ranging from 3 days to 224 months, with the median time being 6 months. The mean (± standard deviation [SD]) follow-up time was 70.3 ± 32.9 months.
Technical Outcome
Among the 44 interventions (17 PTA and 27 stenting) performed, 35 were primary interventions and the remaining nine were secondary treatments for restenosis. The overall technical success rate was 95.5%. Better technical success rate was yielded with stent insertion (100%) than with PTA (88.2%). No major complication or immediate graft loss during intervention was encountered. Four (9.1%) minor complications including a self-limiting, non-obstructive dissection in external iliac artery and three puncture site haematomas resolved on conservative treatment.
The overall re-stenosis rate in primary PTA or stenting Abbreviations: EIA = external iliac artery; IIA = internal iliac artery; TRAS = transplant renal artery stenosis. * Data are shown as mean ± standard deviation, No., or No. (%), unless otherwise stated. † Including diabetes nephropathy (n = 2), renal stones disease (n = 2), systemic lupus erythematosus (n = 2), reflux nephropathy (n = 1), hypertensive nephrosclerosis (n = 1), and focal segmental glomerulosclerosis (n = 1). ‡ Multiple sites of arterial stenosis were present in 4 patients. was 25.7%. There was no significant difference in the re-stenosis rate between the PTA (25.0%) and stenting (26.1%) groups (p = 1.0). Secondary patency was 100% with the nine secondary interventions (5 PTA, 4 stenting) at the last follow-up (mean ± SD, 70.8 ± 36.0 months).
Clinical Outcome
Among the 22 cases presenting with graft dysfunction, the mean decrease in post-intervention serum creatinine level was 87 μmol/l (95% confidence interval [CI], 11.2-162.1) at 3 months (p < 0.05) and 55 μmol/l (95% CI, 18.5-91.8) at 1 year (p = 0.005). Clinical success rate was 100% in this group. There was a significant, though small, decrease in the mean creatinine level in all procedures (n = 44): 46 μmol/l (95% CI, 7.6-84.6) at 3 months (P<0.05) and 24 μmol/l (95% CI, 2.9-45.8) at 1 year (p < 0.05).
In the 16 cases presenting with hypertension, significant improvement in post-procedure SBP was observed at 3 months (mean ± SD decrease, 14 ± 16.7 mm Hg, p < 0.05), 1 year (15 ± 15.8 mm Hg, p = 0.005), and 2 years (16 ± 16.1 mm Hg, p < 0.005). Significant drop in DBP was only present at 3 months after intervention, with a mean decrease of 5 ± 7.8 mm Hg (p < 0.05). These patients required a mean of 4.2 ± 1 medications for blood pressure control, compared with a mean of 3.4 ± 1 antihypertensive medications after intervention (p < 0.05). Clinical success rate was 94% in this hypertensive group achieving improvement in blood pressure control.
Among all the 44 procedures, statistically significant decrease in both SBP and DBP was observed at 3 months, 1 year, and 2 years post-intervention (p < 0.05), and in creatinine level at 3 months and 1 year (p < 0.05) [ Table 2 ].
Among the six asymptomatic patients with TRAS diagnosed by abnormal Doppler sonographic findings (mean peak systolic velocity, 439 ± 138 cm/s), the serum creatinine levels and blood pressure control remained stable after the intervention at 3 months and 1 year, respectively.
No patient mortality or cardiovascular mortality was observed till the last follow-up (mean, 70.8 ± 36.0 months).
Four graft losses were encountered during follow-up at 25 to 112 months (Table 3) . Two had recurrence of initial disease; one had cholesterol embolism which could be attributed to both the prior renal artery stenosis and the associated hypertension; one had chronic deterioration due to unknown cause, with no recurrent TRAS and biopsy showing no acute rejection.
Estimated dialysis-free allograft survival after endoluminal intervention was 100% at 1 year and 97% at 5 years ( Figure 2 ). There was no significant difference Mean ± standard deviation Table 3 . Causes and duration of graft loss in TRAS after PTA/stenting.
Abbreviations: Cr = creatinine; IgA = immunoglobulin A; PTA = percutaneous transluminal angioplasty; TRAS = transplant renal artery stenosis.
in graft survival between primary and secondary intervention groups (p > 0.05) as shown in Figure 3 .
In the long term, persistent improvement (45.7%) or stabilisation (22.8%) of creatinine level was sustained 
DISCUSSION
Percutaneous intervention is nowadays commonly advocated for the primary treatment of TRAS, while surgical revascularisation generally has been reserved for patients not amenable to percutaneous intervention. Surgical dissection of the renal and iliac vessels is technically demanding, accounted by the variable anatomy and extensive fibrosis that frequently develops around the kidney which nearly always involves the renal vessels. 5 Surgery carries a significant risk of graft loss (up to 15% to 20%), ureteral injury (14%), re-operation (13%), and mortality (5%).
1 On the other hand, reported complications in endovascular intervention occur in up to 10% of cases, including haematoma at femoral artery puncture site, intimal flaps, arterial rupture, arterial dissection, and thrombosis. Contrast hypersensitivity and nephropathy are also potential complications upon intravenous contrast use. No significant complications were recorded in our study, except a self-limiting, non-obstructive dissection in the external iliac artery and three puncture site haematomas in the groin (9.1%).
A number of observational studies have illustrated the potential benefits of endoluminal intervention in TRAS. Relevant studies in recent 10 years generally favoured an improved hypertension control and creatinine levels (Table 4) . 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] Some also demonstrated improved glomerular filtration rate. These studies, however, generally comprised a small sample size with 8 to 26 patients or interventions. 3, [6] [7] [8] [11] [12] [13] [14] One of these studies with a larger sample size of 62 PTA/stenting elicited an early statistically significant (p < 0.05) drop in creatinine and blood pressure only at 1 month after the procedure but not at 6 or 12 months. 10 Another study with 32 stenting procedures and long follow-up of a mean of 85.2 months, however, lacked statistical correlation and support.
9 Two of these studies were conducted among Chinese populations, 8, 12 and were, again, limited by a small sample size. In our current study, we recruited a relatively bigger sample size of 44 PTA/stenting with a relatively long follow-up period (mean, 70.3 months) in the Chinese population. We demonstrated a persistent, statistically significant improvement in creatinine and blood pressure in both short and intermediate term. High clinical success rates were observed in patients presenting with graft dysfunction (100%) and hypertension (94%).
Nevertheless, long-term outcome of renal allograft after endoluminal intervention is still poorly documented, with conflicting observations. Ghazanfar et al 15 reported an improved 5-year graft survival rate of 86% in 44 patients with PTA versus patients undergoing surgery or conservative medical treatment. On the contrary, Audard et al 16 reported significantly worse transplant survival in 29 patients undergoing angioplasty with or without stenting for TRAS compared with controls without TRAS, partly attributed to three immediate graft losses which were procedure-related. 16 Our data aided to support a favourable long-term outcome after percutaneous intervention, with high estimated dialysisfree allograft survival of 97% at 5 years. Long-term clinical success in hypertensive control was relatively sustained (84.6%) while that in creatinine level it was only partially sustained (68.5%) with a mean follow-up duration of 70.3 months.
We observed no significant difference in re-stenosis rates between PTA (25%) and stenting (26.1%) groups. This is in contrast to some studies which found an increased re-stenosis rate in PTA without stent placement. One study reported a re-stenosis rate of up to 62% in a group of 21 patients undergoing PTA with a mean follow-up of 95.8 months, compared with 30% in 10 stent implantation procedures. 17 Yet, we reported a relatively higher technical success rate with stent insertion (100%) versus PTA (88.2%). Nonrandomisation of patients undergoing PTA or stenting is a potential limitation for a fair, direct comparison between the stenting and non-stenting groups. Further large-scale randomised controlled trials are required to justify any long-term outcome benefit of PTA with stenting over no stenting.
CONCLUSION
Our study suggests that percutaneous endoluminal intervention for haemodynamically significant TRAS is a safe procedure with high technical success, showing beneficial effects in improving allograft function and blood pressure in the short and intermediate term, as well as a good long-term graft survival and sustained clinical success in hypertensive control in the Chinese population. Long-term clinical success in improving or stabilising graft dysfunction, however, was partially sustained.
